Merger and Acquisition Scenario
Par Pharmaceutical Cos Inc (PRX) and Halozyme Therapeutics Inc (HALO)
| Date: | Apr 14, 2012 |
|---|---|
| Format: | HTML |
| Price: | $250.00 |
Abstract
Revere Data's Merger & Acquisition Scenario Report offers independent, objective and insightful analysis into a hypothetical combination of Par Pharmaceutical Cos Inc (PRX) with Halozyme Therapeutics Inc (HALO) . The Revere report begins by identifying Par Pharmaceutical Cos Inc products that are either complementary or overlapping to Halozyme Therapeutics Inc products. Par Pharmaceutical Cos Inc suppliers are then displayed alongside Halozyme Therapeutics Inc suppliers, with overlapping suppliers to both firms highlighted. Dependent suppliers to both companies are also displayed, including the percentage of dependent revenue if known. Top Par Pharmaceutical Cos Inc customers and top Halozyme Therapeutics Inc customers, including overlapping customers, are also shown. The Revere report then includes key business relationship data in the area of strategic partnerships for each company. Additional content and features include Lines of Business Summaries, Product Summaries, Individual Par Pharmaceutical Cos Inc Product Line and Halozyme Therapeutics Inc Product Line Details, Par Pharmaceutical Cos Inc Earnings and Halozyme Therapeutics Inc Earnings Summaries, and pro forma financial statements. Revere Data Merger & Acquisition Scenario Reports are an essential source of competitive insight into an array of potential merger, acquisition, takeover, consolidation, rollup or other combination scenarios, with particular focus in the healthcare, biotechnology, information technology, finance and media sectors. Revere's extensive databases on key business relationships, product lines, focused sectors, and financial performance indicators provide a rich and integrated information source for investment banking, corporate finance, C-level executives, management consultants, marketing, and business intelligence professionals who want actionable answers and ideas in seconds.
Report Contents
- Summary
- Lines of Business Summary
- Product Summary
- Overlap & Complementary Sectors
- Sample Products in Similar Lines of Business
- Sample Products in Complementary Lines of Business
- Business Relationship Summary
- Top Key Suppliers
- Top Key Customers
- Key Financial Summary
- Individual Company Summary
- Focused Sector
- Revenue/Earnings Summary
- Business Description
- Product Summary
- Product Details
- Relationship Details
- Key Competitors
- Dependent Suppliers
- Key Customers
- Key Partners
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
Companies Mentioned in the Report
- Par Pharmaceutical Cos Inc (PRX) - Overview - Reports
- Halozyme Therapeutics Inc (HALO) - Overview - Reports
More Information:
Learn more about Merger and Acquisition Scenario Report.
Don't see the Scenario report you want? Request Merger and Acquisition Scenario Report »
Download Fact Sheet Merger and Acquisition Scenario (PDF)
Related Reports:
- Merger and Acquisition Scenario for Halozyme Therapeutics, Inc. (HALO) and Par Pharmaceutical Companies, Inc. (PRX)
- Merger and Acquisition Scenario for Vivus Inc (VVUS) and Par Pharmaceutical Cos Inc (PRX)
- Merger and Acquisition Scenario for Baxter International Inc. (BAX) and Par Pharmaceutical Companies, Inc. (PRX)
- Merger and Acquisition Scenario for Dr Reddy'S Laboratories Ltd (RDY) and Par Pharmaceutical Cos Inc (PRX)